JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84

Benzinga Newsdesk www.benzinga.com Positive 65.0%

Neg 0% Neu 0% Pos 65%

JP Morgan initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $84.